Return to Trial Database

BTCRC-LYM17-145

Phase Ib dose de-escalation study of the PI3K alpha/delta inhibitor, Copanlisib given in combination with the immunotherapeutic agents, Nivolumab and Rituximab in patients with relapsed/refractory indolent lymphoma. Big Ten Cancer Research Consortium BTCRC-LYM17-145

Status

Study Completed

Cancer Type(s)

Study Contact

Trial Locations

All sites in which the trial BTCRC-LYM17-145 being conducted in.

No data was found